ABIVAX strengthens its Senior Leadership Team by appointing Dr. Jean-Marc Steens, M.D. as the company’s Chief Medical Officer

Paris, 23rd September 2015 – ABIVAX (Euronext Paris: FR0012333284 – ABVX), a publicly traded, clinical stage biotech company developing and commercializing anti-viral drugs and therapeutic vaccines, today announced the appointment of Dr. Jean-Marc Steens, M.D. as its Chief Medical Officer. 

Dr. Steens joins ABIVAX with almost three decades of experience in the biopharmaceutical industry. During these years, he held critical leadership roles with a focus on viral diseases (especially HIV/AIDS, but also hepatitis B) in both global clinical development and medical affairs. Furthermore, he has lived and worked in Europe and in the Unites States, and has had roles whose scope also included developing markets.

Press contacts

Caroline Carmagnol 

abivax@alizerp.com

+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65

 Standard: +33 1 53 83 08 41